Prosta Shield
Prosta Shield, licence 80105228: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Rapha Canadian Natural
- NPN or DIN-HM
- 80105228
- Status
- Active licence
- Licence date
- 14 October 2020
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
- Conditions légales
Prunus africana (Hook. f.) Kalkman: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Lepidium meyenii Walp.: L'absence d'alcaloïdes doit être démontrée par des rapports d'analyse.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Lycopène Source : Lycopène | 375.0 mcg | Not calculated |
| Prunus africana Source : Ecorce (tronc) Extract : Matériel brut sec Extraction ratio : 4.0:1.0 Dry plant equivalent : 40.0 mg | 10.0 mg | Not calculated |
| Vitamine D Source : Cholécalciférol | 2.5 mcg | 5 µg |
| Panax ginseng Source : Racine Extract : Matériel brut sec Extraction ratio : 8.0:1.0 Dry plant equivalent : 240.0 mg Potency : 5.0 % Total ginsenosides | 30.0 mg | Not calculated |
| Lepidium meyenii Source : Racine Extract : Matériel brut sec Extraction ratio : 6.0:1.0 Dry plant equivalent : 900.0 mg | 150.0 mg | Not calculated |
| Zinc Source : Citrate de zinc | 7.5 mg | 15,000 µg |
| Ginkgo biloba Source : Feuille Extract : Matériel brut sec Extraction ratio : 50.0:1.0 Dry plant equivalent : 2500.0 mg Potency : 6.0 % Terpene lactones | 50.0 mg | Not calculated |
| Ginkgo biloba Source : Feuille Potency : 24.0 % Flavonoid glycosides | Not specified | Not calculated |
| Serenoa repens Source : Fruit Extract : Matériel brut sec Extraction ratio : 10.0:1.0 Dry plant equivalent : 1800.0 mg | 180.0 mg | Not calculated |
Non-medicinal ingredients
Hypromellose, Stéarate de magnésium, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe masculin | minimum: 18.0 Année(s) | 2.0 Capsule | 1.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Used in Herbal Medicine to help relieve the urologic symptoms (e.g. weak urine flow/ incomplete voiding/frequent daytime /night time urination) associated with mild to moderate benign prostatic hyperplasia (BPH).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80105228
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.